Physostigmine reversal of scopolamine-induced hypofrontality

Journal of Cerebral Blood Flow and Metabolism

Volumn 17, Issue 2, 1997, Pages 220-228

  Prohovnik, I ^a   Arnold, S E ^b   Smith, G ^b   Lucas, L R ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Acetyl cholinesterase inhibitors; Alzheimer's disease; Cerebral metabolism; Cerebral perfusion; Neostigmine; Physostigmine; Scopolamine; Tacrine

Indexed keywords

PHYSOSTIGMINE; TACRINE;

ADULT; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN PERFUSION; CHOLINERGIC NERVE; HUMAN; MALE; NORMAL HUMAN; PARIETAL LOBE; PRIORITY JOURNAL;

EID: 0031045161     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004647-199702000-00012     Document Type: Article

References (53)

1. Aarsland D, Larsen JP, Reinvang I, Aasland AM (1994) Effects of cholinergic blockade on language in healthy young women: implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain 117(Pt 6):1377-1384
2. Aubineau P, Sercombe R (1977) Evidence for a double cholinergic mechanism capable of reducing the tone of cerebral arteries. Acta Neurol Scand 56(suppl. 64):296-297
3. Bun J, Piercey MF, Giuffra ME, Mouradian MM, Chase TN (1994) Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. J Neurol Sci 123:44-51
4. Brun A (1987) Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr 6:193-208
5. Buschke H (1973) Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav 12:543-550
6. Christensen H, Maltby N, Jorm AF, Creasey H, Broe GA (1992) Cholinergic "blockade" as a model of the cognitive deficits in Alzheimer's disease. Brain 115(Pt 6):1681-1699
7. Dauphin F, Lacombe P, Sercombe R, Hamel E, Seylaz J (1991) Hypercapnia and stimulation of the substantia innominata increase rat frontal cortical blood flow by different cholinergic mechanisms. Brain Res 553:75-83
8. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, Fowler JS, Volkow ND, Wolf AP (1993) Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 90:11816-11820
9. Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. Arch Neurol 30:113-121
10. Ebmeier KP, Hunter R, Curran SM, Dougal NJ, Murray CL, Wyper DJ, Patterson J, Hanson MT, Siegfried K, Goodwin GM (1992) Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Psychopharmacology 108(1-2):103-109
11. Edvinsson L, MacKenzie ET, McCulloch J (1993) Cerebral Blood Flow and Metabolism, New York, Raven Press, pp 285-312
12. 18F]fluorodeoxy-glucose. J Comput Assist Tomogr 7:590-598
13. Fukuyama H, Ouchi Y, Matsuzaki S, Ogawa M, Yamauchi H, Nagahama Y, Kimura J, Yonekura Y, Tsukada H (1995) Focal cortical CBF activation is regulated by cortical intrinsic cholinergic neurons. J Cereb Blood Flow Metab 15(suppl 1):S507
14. Galea E, Shaw CF, Triguero D, Estrada C (1991) Choline acetyltransferase activity associated with cerebral cortical microvessels does not originate in basal forebrain neurons. J Cereb Blood Flow Metab 11:875-878
15. Geaney DP, Soper N, Shepstone BJ, Cowen PJ (1990) Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet 335:1484-1487
16. Gitelman DR, Prohovnik I (1992) Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging 13:313-318
17. Goodman Gilman A, Goodman LS, Rall TW, Murad F (1985) The Pharmacological Basis of Therapeutics, 7th ed, New York, Macmillan Publishing Company, p 116
18. Gustafson L, Edvinsson L, Dahlgren N, Hagberg B, Risberg J, Rosen I, Ferno H (1987) Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow measurement, and EEG. Psychopharmacology 93:31-35
19. Honer WG, Prohovnik I, Smith G, et al. (1988) Scopolamine reduces frontal cortex perfusion. J Cereb Blood Flow Metab 8:635-641
20. Hunter R, Wyper DJ, Patterson J, Hansen MT, Goodwin GM (1991) Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography. Br J Psychiatry 158:351-357
21. Jagust WJ, Budinger TF, Reed BR (1987) The diagnosis of dementia with single photon emission computed tomography. Arch Neurol 44:258-262
22. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1973a) Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry 130:1370-1376
23. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1973b) Parasympathetic suppression of manic symptoms by physostigmine. Arch Gen Psychiatry 28:542-547
24. Kalaria RN, Homayoun P, Whitchouse PJ (1994) Nicotinic cholinergic receptors associated with mammalian cerebral vessels. J Auton Nerv Syst 49:S3-S7
25. Kiyosawa M, Baron JC, Hamel E, Pappata S, Duverger D, Riche D, Mazoyer B, Naquet R, MacKenzie ET (1989) Time course of effects of unilateral lesions of the nucleus basalis of Meynert on glucose utilization by the cerebral cortex. Brain 112:435-455
26. Kurumaji A, Dewar D, McCulloch J (1993) Metabolic mapping with deoxyglucose autoradiography as an approach for assessing drug action in the central nervous system. In: Imaging Drug Action in the Brain (London ED, ed), Boca Raton, Fla., CRC Press, pp 207-246
27. Lines CR, Dawson C, Preston GC, Reich S, Foster C, Traub M (1991) Memory and attention in patients with senile dementia of the Alzheimer type and in normal elderly subjects. J Clin Exp Neuropsychol 13(5):691-702
28. Linville DG, Giacobini E, Arneric SP (1992) Heptyl-physostigmine enhances basal forebrain control of cortical cerebral blood flow. J Neurosci Res 31(3):573-577
29. Maximilian VA, Prohovnik I, Risberg J (1980) Cerebral hemodynamic response to mental activation in normo- and hypercapnia. Stroke 11:342-347
30. McCulloch J (1988) The physiology and regulation of cerebral blood flow. In: Handbook of Regional Cerebral Blood Flow (Knezevic S, Maximilian VA, Mubrin Z, Prohovnik I, Wade J, eds) Hillsdale, NJ, Lawrence Erlbaum Associates, pp 1-24
31. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, Sunderland T (1992) Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 17(3):215-226
32. Molchan SE, Matochik JA, Zametkin AJ, Szymanski HV, Cantillon M, Cohen RM, Sunderland T (1994) A double FDG/PET study of the effects of scopolamine in older adults. Neuropsychopharmacology 10:191-198
33. Molnar L, Hegedus K, Fekete I (1991) Difference between the cerebrovascular effect of purinergic Co-ATP and that of the cholinesterase inhibitor, physostigmine, in vivo. Eur J Pharmacol 209(1-2):81-86
34. Moro V, Badaut J, Springhetti V, Edvinsson L, Seylaz J, Lasbennes F (1995) Regional study of the colocalization of neuronal NOS with muscarinic receptors in the rat. J Cereb Blood Flow Metab 15(suppl 1):S452
35. Neufeld MY, Rabey MJ, Parmet Y, Sifris P, Treves TA, Korczyn AD (1994) Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's disease patients and age-matched controls. Electroencephalogr Clin Neurophysiol 91(6):407-412
36. Nordberg A (1993) Effect of long-term treatment with tacrine in Alzheimer's disease as visualized by PET. Acta Neurol Scand suppl 149:62-65
37. Ogawa M, Magata Y, Ouchi Y, Fukuyama H, Yamauchi H, Kimura J, Yonekura Y, Konishi J (1994) Scopolamine abolishes cerebral blood flow response to somatosensory stimulation in anesthetized cats: PET study. Brain Res 650(2):249-252
38. Peruzzi P, Lacombe P, Moro V, Vaucher E, Levy F, Seylaz J (1993) The cerebrovascular effects of physostigmine are not mediated through the substantia innominata. Exp Neurol 122:319-326
39. Prohovnik I (1988) Data quality, integrity and interpretation. In: Handbook of Regional Cerebral Blood Flow (Knezevic S, Maximilian VA, Mubrin Z, Prohovnik I, Wade J, eds), Hillsdale. NJ, Lawrence Erlbaum Associates, pp 37-50
40. Prohovnik I, Alexander GA, Davidson M. Frontal cortex perfusion enhanced by THA in Alzheimer's disease. Presented at the Third International Springfield Symposium on Advances in Alzheimer Therapy, Springfield, IL, May 3-5, 1994.
41. 133Xe clearance. In: Functional Radionuclide Imaging of the Brain (Magistretti P, ed), New York, Raven Press
42. Prohovnik I, Mayeux R, Sackeim HA, Smith G, Stern Y, Alderson PO (1988) Cerebral perfusion as a diagnostic marker in early Alzheimer's disease. Neurology 38:931-937
43. Ray PG, Meador KJ, Loring DW, Murro AM, Buccafusco JJ, Yang XH, Zamrini EY, Thompson WO, Thompson EE (1991) Effects of scopolamine on visual evoked potentials in aging and dementia. Electroencephalogr Clin Neurophysiol 80:347-351
44. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Crockford HA, Crooks M, Hill K, Levy R (1993) Further analysis of the cognitive effects of THA in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 110:395-401
45. Sato A, Sato Y (1992) Regulation of regional cerebral blood flow by cholinergic fibers originating in the basal forebrain. Neurosci Res 1992;14:242-274
46. Schaffer CB, Pandey GN, Noll KM, Killian GA, Davis JM (1981) Introduction and theories of affective disorders. In: Neuropharmacology of Central Nervous System and Behavioral Disorders (Palmer GC, ed), New York, Academic Press
47. Scremin OU, Rovere AA, Raynald AC, Giardini A (1973) Cholinergic control of blood flow in the cerebral cortex of the rat. Stroke 4:232-239
48. Scremin OU, Scremin AM, Somani SM, Giacobini E (1990) Brain regional distribution of physostigmine and its relation to cerebral blood flow following intravenous administration in rats. J Neurosci Res 26(2):188-195.
49. Standaert FG (1990) Neuromuscular physiology. In: Anesthesia, 3rd ed (Miller RD, ed), New York, Churchill Livingstone, p 681
50. Vaucher E, Dauphin F, Seylaz J, Lacombe P (1994) Autoradiographic study of the cerebrovascular effects of stimulation of the substantia innominata. J Auton Nerv Syst 1994;49:S43-S47
51. Vaucher E, Hamel E, Seylaz J, Lacombe P (1995) Uncoupling of local cerebral blood flow and glucose utilization during basal forebrain stimulation. J Cereb Blood Flow Metab 1995; 15(Suppl. 1):S493
52. Wesnes KA, Simpson PM, White L, Pinker S, Jertz G, Murphy M, Siegfried K (1991) Cholinesterase inhibition in the scopolamine model of dementia. Ann NY Acad Sci 640:268-271
53. Wirkowski E, Prohovnik I, Young WL (1991) Observations on the physostigmine syndrome in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 3:73-75